2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-178430S
    Octadecanedioic acid-d32
    Octadecanedioic acid-d32 is the deuterium labeled Octadecanedioic acid (HY-W005178). Octadecanedioic acid is an endogenous metabolite. Octadecanedioic acid can be used in the research of Reye's syndrome.
    Octadecanedioic acid-d32
  • HY-178787S
    POPG-d62
    POPG-d62 (PG(16:0/18:1)-d62) is the deuterium labeled POPG (HY-142991). POPG sodium salt is a negatively charged phospholipid. POPG sodium salt affects the interactions of membrane proteins with other molecules by changing the charge characteristics of the lipid environment. POPG sodium salt increases the apparent affinity of Gαq and Gβ1γ1 for activated NTS1. POPG sodium salt can interact with the positive charge of peptides. POPG sodium salt can be used in Parkinson's disease research.
    POPG-d62
  • HY-179008A
    (S)-5-HT2CR agonist 1 2841458-00-0
    (S)-5-HT2CR agonist 1 (Compound (S)-16k) is selective 5-HT2CR agonist, with an EC50 of 14 nM. FXa-IN-2 can be used in the research of hyperlocomotion.
    (S)-5-HT2CR agonist 1
  • HY-179164S
    Choline-15N chloride 287484-43-9
    Choline-15N chloride is the 15N-labeled Choline chloride (HY-B1337). Choline chloride is an essential nutrient that activates?alpha7 nicotinic receptors?and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders
    Choline-15N chloride
  • HY-179350A
    EG01449 98%
    EG01449 is a quinoline-based antagonist of Neuropilin-1 (NRP1) with an Kd of 0.6 µM. EG01449 competitively inhibits the binding of VEGFA to NRP1 with an IC50 of 362 nM. EG01449 prevents VEGFA-induced pain by inhibiting NRP1-dependent signaling and reducing sodium currents in sensory neurons. EG01449 can be used for the research of nociceptive pain.
    EG01449
  • HY-179724A
    PZ-1657 hydrochloride 98%
    PZ-1657 hydrochloride (Compound 57) is a potent, selective and orally active 5-HT7 receptor inverse agonist with a Ki of 5 nM. PZ-1657 hydrochloride can inhibit the constitutive cAMP production mediated by the Gs signaling pathway (EC50 = 2.93 nM). PZ-1657 hydrochloride can significantly reduce the MMP-9 activity mediated by 5-HT7 receptors in the hippocampus of mice, and the effect is comparable to that of SB-269970 (HY-15370). PZ-1657 hydrochloride can reverse the cognitive deficits observed in the rat novel object recognition test induced by Phencyclidine without affecting the animals' spontaneous activities. PZ-1657 hydrochloride can be used for the research of emotional disorders, such as depression and bipolar disorder.
    PZ-1657 hydrochloride
  • HY-180212A
    SYK-1106 dihydrochloride
    SYK-1106 dihydrochloride is a selective δ opioid receptor (DOR) agonist with an EC50 of 0.089 nM. SYK-1106 dihydrochloride shows high selectivity over MOR and KOR. SYK-1106 dihydrochloride exhibits antidepressant-like effects in the mouse forced-swimming tests. SYK-1106 dihydrochloride can be used for the research of depression.
    SYK-1106 dihydrochloride
  • HY-18100AR
    PRE-084 hydrochloride (Standard) 75136-54-8 98%
    PRE-084 (hydrochloride) (Standard) is the analytical standard of PRE-084 (hydrochloride). This product is intended for research and analytical applications. PRE-084 hydrochloride is a highly selective σ1 receptor (S1R) agonist, with an IC50 of 44 nM. PRE-084 hydrochloride exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 hydrochloride also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway.
    PRE-084 hydrochloride (Standard)
  • HY-18102BS
    GLPG0492-13C,d3 racemate 98%
    GLPG0492-13C,d3 racemate is 13C-labeled GLPG0492 (racemate) (HY-18102B). GLPG0492 racemate is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 racemate exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 racemate effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 racemate prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy.
    GLPG0492-13C,d3 racemate
  • HY-181559S
    VU6025733 98%
    VU6025733 (AG06827) is a highly selective, orally active and blood-brain barrier-penetrant positive allosteric modulator of the muscarinic acetylcholine receptor subtype M4 (M4 mAChR). VU6025733 exerts a potentiating effect on acetylcholine-induced receptor activation with an EC50 of 23 nM for hM4 and 55 nM for rM4. VU6025733 shows high selectivity over other muscarinic acetylcholine receptor subtypes, dose-dependently reduces amphetamine-induced hyperlocomotion in rats. VU6025733 is applicable to the research of schizophrenia, Parkinson's disease, and Alzheimer's disease.
    VU6025733
  • HY-182096A
    DSPE-PEG2000-MG1
    DSPE-PEG2000-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG2000-KTP can be used for drug delivery.
    DSPE-PEG2000-MG1
  • HY-182096B
    DSPE-PEG3400-MG1
    DSPE-PEG3400-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG3400-KTP can be used for drug delivery.
    DSPE-PEG3400-MG1
  • HY-182096C
    DSPE-PEG5000-MG1
    DSPE-PEG5000-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG5000-KTP can be used for drug delivery.
    DSPE-PEG5000-MG1
  • HY-183657A
    GPR3 inverse agonist-1 TFA 98%
    GPR3 inverse agonist-1 TFA is a selective and competitive GPR3 inverse agonist with an EC50 of 5 μM. GPR3 inverse agonist-1 TFA inhibits GPR3-dependent Gs activity, stabilizes a specific receptor conformation, and reduces cAMP levels. GPR3 inverse agonist-1 TFA can be used for the research of Alzheimer's disease.
    GPR3 inverse agonist-1 TFA
  • HY-184129A
    (E)-IDO1/TDO-IN-15 2414964-76-2
    (E)-IDO1/TDO-IN-15 is an isomer of IDO1/TDO-IN-15 (HY-184129). IDO1/TDO-IN-15 is a dual IDO1/TDO inhibitor with an IDO1 IC50 of 0.19 μM and a TDO IC50 of 0.37 μM. (E)-IDO1/TDO-IN-15 is applicable to the research of cancer and Alzheimer's disease.
    (E)-IDO1/TDO-IN-15
  • HY-185234A
    (R)-CTR/AMYR activator-1 3068778-30-0 98%
    (R)-CTR/AMYR activator-1 (Compound 122) is a CTR/AMYR activator with EC50 values of 0.8 and 0.73 nM. (R)-CTR/AMYR activator-1 can used for the researches of bone diseases, metabolic diseases, cardiovascular diseases, and neurodegenerative diseases.
    (R)-CTR/AMYR activator-1
  • HY-186059A
    HCN2 modulator-5 3080809-02-2
    HCN2 modulator-5 (S-configuration 39) is a HCN2 ion channel inhibitor. HCN2 modulator-5 inhibits HCN2 ion channel activity. HCN2 modulator-5 can be used for the research of pain, inflammatory pain, neuropathic pain, tinnitus, central nervous system disorders, psychiatric disorders, mood disorders.
    HCN2 modulator-5
  • HY-186061A
    HCN2 modulator-8 3080809-12-4
    HCN2 modulator-8 is a pyrazolopyridine derivative and selective HCN2 inhibitor. HCN2 modulator-8 can be used for the research of pain, tinnitus, central nervous system disorders, psychiatric disorders, mood disorders.
    HCN2 modulator-8
  • HY-186105A
    (-)-P7C3-S243 1597443-57-6 98%
    (-)-P7C3-S243 is an orally active, blood-brain barrier permeable neuroprotective agent. (-)-P7C3-S243 binds to μ-opioid Receptor and TSPO. (-)-P7C3-S243 inhibits the premature apoptosis death of newborn hippocampal neurons, protects mature nigral dopaminergic neurons, promotes neuronal survival and prevents cognitive impairment. (-)-P7C3-S243 ameliorates depression-like behaviors in rat models. (-)-P7C3-S243 is applicable to research related to Parkinson's disease and Alzheimer's disease.
    (-)-P7C3-S243
  • HY-186116A
    LSD1-IN-49 hydrochloride 1422534-06-2
    LSD1-IN-49 hydrochloride (Compound (±) 1) is an irreversible LSD1/KDM1A inhibitor with an IC50 of 29 nM against hLSD1. LSD1-IN-49 hydrochloride irreversibly inhibits the enzymatic activity of LSD1 by forming an adduct with flavin adenine dinucleotide (FAD) in the binding pocket of LSD1. LSD1-IN-49 hydrochloride is applicable to research related to schizophrenia, autism spectrum disorder and Huntington's disease.
    LSD1-IN-49 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity